IRIDEX (NASDAQ:IRIX) Issues Earnings Results

IRIDEX (NASDAQ:IRIX) announced its quarterly earnings data on Thursday. The medical equipment provider reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05), Zacks reports. The company had revenue of $12.70 million during the quarter, compared to the consensus estimate of $12.80 million. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%.

IRIDEX Price Performance

NASDAQ:IRIX opened at $1.00 on Friday. The company has a market cap of $16.62 million, a P/E ratio of -1.49 and a beta of 0.94. The firm’s fifty day moving average price is $1.37 and its two-hundred day moving average price is $1.58. IRIDEX has a one year low of $0.78 and a one year high of $3.65. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.54 and a quick ratio of 0.85.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on IRIDEX in a research report on Tuesday. They set a “hold” rating on the stock.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.